Skip to main content

Carlos Molina Cateriano

Institutions of which they are part

Head of group
Stroke research
Vall Hebron Institut de Recerca

Carlos Molina Cateriano

Institutions of which they are part

Head of group
Stroke research
Vall Hebron Institut de Recerca

Projects

NORA-HOME. EFICIENCIA Y SEGURIDAD DE UN MODELO DE MONITORIZACION MULTIMODAL AMBULATORIA EN PACIENTES CON ICTUS MINOR Y AITS.

IP: Mª Ángeles Muchada López
Collaborators: Carlos Molina Cateriano, Alvaro Garcia Tornel Garcia Camba, Marc Rodrigo Gisbert
Funding agency: Instituto de Salud Carlos III
Funding: 123420
Reference: PI22/01928
Duration: 01/01/2023 - 31/12/2025

TRUSTroke: TRUSTWORTHY PREDICTION OF STROKE OUTCOME ON A FEDERATED LEARNING INFRASTRUCTURE

IP: Carlos Molina Cateriano
Collaborators: Estela Sanjuan Menendez, Laura Rivera Sanchez, Federica Rizzo, Marta Aurora Rubiera Del Fueyo, David Rodriguez Luna
Funding agency: EUROPEAN COMMISSION
Funding: 760000
Reference: TRUSTROKE_HE-HLTH-STAYHLTH2022
Duration: 01/05/2023 - 30/04/2027

Aplicación de estrategias basadas en ciencia de datos y machine learning en la investigación en ictus

IP: Carlos Molina Cateriano
Collaborators: Marta Olive Gadea
Funding agency: Fundació Institut de Recerca HUVH
Funding: 117000
Reference: HUVH/BPFSE_RENOV/2021/OLIVÉ
Duration: 01/06/2021 - 30/05/2023

RES-Q PLUS: Comprehensive solutions of healthcare improvement based on the global Registry of Stroke Care Quality

IP: Carlos Molina Cateriano
Collaborators: Noelia Rodríguez Villatoro, Federica Rizzo, David Rodriguez Luna, Carole Conforti
Funding agency: EUROPEAN COMMISSION
Funding: 396730
Reference: RES-Q PLUS_HE-HLTH-TOOL21
Duration: 01/11/2022 - 31/10/2026

Related news

UMBRELLA, a consortium of over 20 public and private partners, kicks off this week with the aim of revolutionising the entire stroke care pathway in Europe by adopting a holistic approach that covers stroke diagnosis, prevention and care.

The Consortium will create a platform to facilitate a personalised management for stroke patients, enabling a more efficient personalized monitoring and patient follow up.

Funding is key to bringing the neuroprotective drug ApTOLL to market and providing a new therapeutic option for the patients.

Related professionals

Ingrid Galán Cartaña

Ingrid Galán Cartaña

Senior researcher
Clinical Neuroimmunology
Read more
Masotto , Barbara

Masotto , Barbara

Predoctoral researcher
Genetics Medicine
Read more
Mercedes Martinez Mansilla

Mercedes Martinez Mansilla

Research technician
Translational Molecular Pathology
Read more
Ulloa Navas, Ana Daniela

Ulloa Navas, Ana Daniela

Rheumatology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.